Scientists delve deeper into how vaccines work against leishmaniasis

Scientists have established the effectiveness of vaccines they developed to prevent the disfiguring skin disease leishmaniasis in animal studies, and Phase 1 human trial planning is in motion for the most promising candidate.

Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia

Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis. The deal, announced Monday, is the latest

June 4, 2024

Study Supports More Inclusive Clinical Trials With Broader Eligibility Criteria

Patients who received protocol waivers in a clinical trial of targeted anticancer therapy had outcomes similar to those who met all enrollment criteria, a large

June 28, 2024

A novel synthetic lethal target for ATM inhibitors in pancreatic cancer

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker

November 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.